FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib-containing Regimes: a randomised controlled trial

Trial Profile

FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib-containing Regimes: a randomised controlled trial

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Cyclophosphamide; Cyclophosphamide; Fludarabine; Fludarabine; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms FLAIR
  • Most Recent Events

    • 29 Jun 2017 Planned number of patients changed from 754 to 1576.
    • 29 Jun 2017 Planned End Date changed from 20 Aug 2018 to 1 Jan 2030.
    • 04 Nov 2015 Accrual to date is 27% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top